STRYKER ($SYK) Releases Q3 2026 Earnings

STRYKER ($SYK) reported Q3 2026 earnings of $3.52 per share, missing estimates by $0.06, with revenue of $6.52B, missing estimates by $168.19M. Stock price fell 5.83%. Insiders sold shares, while hedge funds had mixed activity. Analysts' price targets range from $330 to $407.

Original reporting
Published Oct 29, 2026, 8:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
STRYKER ($SYK) Releases Q3 2026 Earnings — source image
Decision brief

The 30-second read

$SYKBearishMed
01

Why it matters

The immediate trading signal is the dual miss (EPS and revenue) versus estimates, which typically leads to estimate cuts and multiple compression until management commentary/guidance clarifies durability.

02

Market read

Traders can use the reported miss versus consensus to reassess near-term expectations and position for follow-on analyst revisions.

03

What to watch

No forward guidance, backlog, or management commentary is included, so traders may be missing the key driver of whether the miss is temporary versus structural.

Relevance 8/10Novelty 8/10Timing: reported Oct 29, after market close (stock down 5.83% since close)

Background

This is an earnings release writeup for Stryker’s Q3 2026 results, including EPS and revenue versus consensus and a same-day price reaction.

Company-level read

Ticker impact

$SYKBearishHigh confidence
Context

Stryker reported Q3 2026 EPS of $3.52, missing $3.58, and revenue of $6.52B, below $6.69B, with the stock down 5.83% since close.

Expected impact

Likely pressure as the market digests the EPS and revenue shortfalls and adjusts forward estimates.

Evidence & confidence

The article provides the company’s own quarterly results versus estimates and notes a same-day post-close decline of 5.83%, indicating immediate market reaction to the miss.

Market effects

As a large medical device name, the miss can modestly weigh on sentiment for medtech earnings expectations, though no sector-wide guidance is provided here.

Primarily US large-cap medtech sentiment; no regional macro or policy linkage is described.

Limited global spillover indicated, since the article contains only company-specific results and insider/13F-style flows.

Counterpoint

The article does not include guidance, margins, or segment detail; the stock drop may overreact if the miss is driven by timing or one-off items not captured here.

Key entities

  • Stryker

    Reported Q3 2026 EPS of $3.52 (vs $3.58 estimate) and revenue of $6.52B (vs $6.69B estimate), with shares down 5.83% since close.

Related articles

Low

Bulgaria accepts first five US M1126 Stryker ICV armored vehicles under $1.4 billion Army modernization.

Bulgaria has received the first five of 183 Stryker armored vehicles under a $1.4 billion modernization deal. The order includes various configurations, with deliveries delayed due to component shortages. General Dynamics Land Systems-Canada manufactures the vehicles, and TEREM-Ivaylo handles final assembly and testing. The project's cost has increased by 2.76% due to inflation and other factors.

$ZBHHighAI 9/10

Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy

Zimmer Biomet (ZBH) shares rose 15% after Q3 sales grew 3.7% in constant currency, with hips, sports medicine, and technology segments growing 7% or more. The company raised its 2026 guidance, citing progress in diversification. Knees, 37% of sales, declined 2.6%. Rival Stryker (SYK) and Smith & Nephew (SNN) also saw gains, despite Smith & Nephew cutting its outlook.